Aktiekurser för samtliga börslistor - Dagens Industri

Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 21 timmar sedan · Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq 2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Protara therapeutics pipeline

2020-07-24 --ArTara Therapeutics, Inc., a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name 21 hours ago 2020-10-05 Protara Therapeutics, Inc. Quote & Chart - Click for current quote - TARA About Protara Therapeutics, Inc. (adapted from Protara Therapeutics, Inc. prospectus): They are committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. Our early pipeline includes programs in genetically defined oncology and immunology indications. Powered for Partnership We believe in exploring potential synergies with the biopharmaceutical industry to accelerate the path forward to becoming a fully integrated biotechnology company and delivering transformative therapies to the broadest possible patient populations. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with Using scientific know-how to investigate additional potential of Protara’s pipeline. Köp aktier i Protara Therapeutics Inc - enkelt och billigt hos Avanza Bank.

The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.

Aktiekurser för samtliga börslistor - Dagens Industri

Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-08-03 Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to … 2021-04-07 Protara Therapeutics, Inc. announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors.

Aktiekurser för samtliga börslistor - Dagens Industri

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-08-03 Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to … 2021-04-07 Protara Therapeutics, Inc. announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors.
Vaxthusgaser procent

Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Pipeline. Our approach has the potential to provide one-time cures for certain rare inherited diseases affecting people around the world. We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

nar borjar skolan stockholm
får man sjukskriva sig för skönhetsoperation
hijab
implicit declaration of function c
receptionist folktandvården lund
salong victoria umea
statistik matte 2b

KALLELSE TILL ÅRSSTÄMMA I WESTPAY AB - Yahoo Finance

The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. Pipeline Overview.